| Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation K Stellos, A Gatsiou, K Stamatelopoulos, L Perisic Matic, D John, ... Nature medicine 22 (10), 1140-1150, 2016 | 257 | 2016 |
| Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer’s disease: from pathophysiology to novel treatment strategies K Sopova, K Gatsiou, K Stellos, C Laske Current Alzheimer Research 11 (1), 27-39, 2014 | 113 | 2014 |
| Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease K Stamatelopoulos, D Sibbing, LS Rallidis, G Georgiopoulos, D Stakos, ... Journal of the American College of Cardiology 65 (9), 904-916, 2015 | 104 | 2015 |
| MicroRNAs in platelet biogenesis and function: implications in vascular homeostasis and inflammation A Gatsiou, JN Boeckel, V Randriamboavonjy, K Stellos Current vascular pharmacology 10 (5), 524-531, 2012 | 80 | 2012 |
| RNA Therapeutics in Cardiovascular Precision Medicine. SK Laina A, Gatsiou A, Georgiopoulos G, Stamatelopoulos K Front Physiol. 25 (9), 953, 2018 | 72* | 2018 |
| Increased myeloperoxidase plasma levels in patients with Alzheimer's disease S Tzikas, D Schlak, K Sopova, A Gatsiou, D Stakos, K Stamatelopoulos, ... Journal of Alzheimer's Disease 39 (3), 557-564, 2014 | 70 | 2014 |
| Increased adenosine-to-inosine RNA editing in rheumatoid arthritis NI Vlachogiannis, A Gatsiou, DA Silvestris, K Stamatelopoulos, ... Journal of autoimmunity 106, 102329, 2020 | 57 | 2020 |
| Adenosine-to-inosine RNA editing in health and disease A Gatsiou, N Vlachogiannis, FF Lunella, M Sachse, K Stellos Antioxidants & Redox Signaling 29 (9), 846-863, 2018 | 46 | 2018 |
| Adenosine-to-inosine Alu RNA editing controls the stability of the pro-inflammatory long noncoding RNA NEAT1 in atherosclerotic cardiovascular disease NI Vlachogiannis, M Sachse, G Georgiopoulos, E Zormpas, D Bampatsias, ... Journal of molecular and cellular cardiology 160, 111-120, 2021 | 43 | 2021 |
| Platelet microRNAs: From platelet biology to possible disease biomarkers and therapeutic targets DA Stakos, A Gatsiou, K Stamatelopoulos, AD Tselepis, K Stellos Platelets 24 (8), 579-589, 2013 | 40 | 2013 |
| Amyloid-β (1-40) and mortality in patients with non–ST-segment elevation acute coronary syndrome: a cohort study K Stamatelopoulos, M Mueller-Hennessen, G Georgiopoulos, M Sachse, ... Annals of internal medicine 168 (12), 855-865, 2018 | 34 | 2018 |
| Endothelial dysfunction and immunothrombosis in sepsis E Maneta, E Aivalioti, S Tual-Chalot, B Emini Veseli, A Gatsiou, ... Frontiers in Immunology 14, 1144229, 2023 | 29 | 2023 |
| Additive contribution of microRNA-34a/b/c to human arterial ageing and atherosclerosis A Gatsiou, G Georgiopoulos, NI Vlachogiannis, L Pfisterer, A Fischer, ... Atherosclerosis 327, 49-58, 2021 | 26 | 2021 |
| Dawn of epitranscriptomic medicine A Gatsiou, K Stellos Circulation: Genomic and Precision Medicine 11 (9), e001927, 2018 | 26 | 2018 |
| Reactive vasodilation predicts mortality in primary systemic light-chain amyloidosis K Stamatelopoulos, G Georgiopoulos, F Athanasouli, PE Nikolaou, ... Circulation research 125 (8), 744-758, 2019 | 25 | 2019 |
| Amyloid-beta (1-40) peptide and subclinical cardiovascular disease K Stamatelopoulos, CJ Pol, C Ayers, G Georgiopoulos, A Gatsiou, ... Journal of the American College of Cardiology 72 (9), 1060-1061, 2018 | 23 | 2018 |
| RNA modifications in cardiovascular health and disease A Gatsiou, K Stellos Nature Reviews Cardiology 20 (5), 325-346, 2023 | 19 | 2023 |
| Clinical frailty, and not features of acute infection, is associated with late mortality in COVID‐19: a retrospective cohort study NI Vlachogiannis, KF Baker, G Georgiopoulos, C Lazaridis, ... Journal of cachexia, sarcopenia and muscle 13 (3), 1502-1513, 2022 | 18 | 2022 |
| Adenosine-to-inosine RNA editing contributes to type I interferon responses in systemic sclerosis NI Vlachogiannis, S Tual-Chalot, E Zormpas, F Bonini, PA Ntouros, ... Journal of Autoimmunity 125, 102755, 2021 | 16 | 2021 |
| Different effects of ranibizumab and bevacizumab on platelet activation profile B Sobolewska, C Grimmel, A Gatsiou, K Sopova, J Klein, T Biedermann, ... Ophthalmologica 234 (4), 195-210, 2015 | 13 | 2015 |
Konstantinos Stellos, MD, FAHA, FESCProfessor of Medicine, Heidelberg University (Germany) & Newcastle University (UK)Verified email at medma.uni-heidelberg.de
